Uniting Biotech & Pharma Experts to Exchange Insights on Oligonucleotide Analytical
Development & CMC
Despite milestone progress, such as Avidity securing breakthrough designation for their oligo conjugate, significant challenges persist across the oligo landscape in impurity profiling, drug characterisation, efficient scale-up, and regulatory alignment.
Join 80+ industry experts from analytical development, process development, CMC, analytical chemistry, and quality control at the 4th Oligonucleotide Analytical Development & CMC Summit to collaborate, network and learn cutting-edge strategies that are tackling the unique challenges in oligo analytical development and CMC scale-up.
Gain actionable insight from case studies, presentations and deep dive discussions from Sarepta, Ionis, Biogen, Novo Nordisk, GSK, Wave Life Science, Denali, PepGen, Avidity, Alnylam and more, to advance and reshape the future of oligonucleotide drug development.
Very intimate conference. Felt connected to the speakers and they were all very approachable and provided excellent dialog
Novo Nordisk
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Other Events in the Series:
